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Abstract
Transient receptor potential vanilloid type 1 (TRPV1) receptor is a non selective ligand-gated cation channel acti-
vated by capsaicin, heat, protons and endogenous lipids termed endovanilloids. As well as peripheral primary affer-
ent neurons and dorsal root ganglia, TRPV1 receptor is also expressed in spinal and supraspinal structures such as
those belonging to the endogenous antinociceptive descending pathway which is a circuitry of the supraspinal
central nervous system whose task is to counteract pain. It includes periaqueductal grey (PAG) and rostral ventro-
medial medulla (RVM) whose activation leads to analgesia. Such an effect is associated with a glutamate increase
and the activation of OFF and inhibition of ON cell population in the rostral ventromedial medulla (RVM). Activa-
tion of the antinociceptive descending pathway via TPRV1 receptor stimulation in the PAG may be a novel strategy
for producing analgesia in chronic pain. This review will summarize the more recent insights into the role of TRPV1
receptor within the antinociceptive descending pathway and its possible exploitation as a target for new pain-killer
agents in chronic pain conditions, with particular emphasis on the most untreatable pain state: neuropathic pain.
TRPV1 receptor: a member of TRP family channels
TRP ion channels described for first time in Drosophila
melanogaster [1] are ion channels that respond to
mechanical, thermal, chemical (i.e. acid, lipids) and
many other stimuli coming from the extra and intracel-
lular milieu [2-5]. The TRP channel family contains
seven divisions: TRPC (canonical), TRPV (vanilloid),
TRPM (melastatin), TRPA (ankyrin), TRPP (policystin)
and TRPML (mucolipin) [2,6-8]. TRPV1, however,
remains the most studied and best characterized TRP
family member, due to the fact that it has been impli-
cated in a wide variety of cellular and physiological pro-
cesses, including noxious physical and chemical stimuli
detection, making it a promising target for pain-relieving
drugs acting exactly where pain originates.
The TRPV1 channel consists of six transmembrane
domains assembled as homo or hetero-tetramers with
each sub-unit contributing to the cation channel struc-
ture [9-11]. It is activated by capsaicin, the pungent
ingredient found in the hot chilli pepper [12], resinifera-
toxin (RTX), a highly irritant diterpene ester isolated
from Euphorbia resinifera [13], noxious heat (> 43°C),
low pH (5.2) [12,14], voltage [15,16] and various endo-
genous lipids such as anandamide which also activates
cannabinoid type 1 (CB1) receptors, 12-hydroperoxy-
eicosatetraenoic acid (12-HPETE) and N-arachidonoyl
dopamine (NADA) [17-19]. Other natural compounds
activating TRPV1 receptor are piperine found in black
pepper, eugenol in cloves and zingerone in horseradish,
allicin present in garlic and onion, gingerols present in
raw ginger and shogaols, which are dehydration pro-
ducts of gingerols present in steamed ginger [20-26]. All
these compounds are lipophilic and therefore bind to
the intracellular surface of TRPV1 receptor [26]. Cam-
phor is a natural compound that activates heterolo-
gously-expressed TRPV1 channels and potentiates
TRPV1 currents in dorsal root ganglia (DRG) neurons
at higher doses and at a different site from capsaicin.
Camphor is used as a topical analgesic since it comple-
tely desensitizes the TRPV1 channel, through a vanil-
loid-independent mechanism and more rapidly than
capsaicin [27]. TRPV1 is directly gated by noxious heat
(> 43°C), which produces a sensation of pain through
direct activation or through the efferent release of pro-
inflammatory neuropeptides (neurogenic inflammation)
[28]. Its expression on free nerve terminals in the skin
allows us to detect nociceptive temperatures and facili-
tates its exposition to several modulators produced in
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response to inflammatory conditions or tissue damage
that potentiate the channel’s response to temperature.
Thus under certain cellular conditions, such as inflam-
mation and ischemia, TRPV1 receptor activation leads
to pain under physiological temperature. The sensitivity
of TRPV1 receptor also depends on membrane potential
since the channel can open in the absence of capsaicin
at room temperature (23°C) at depolarized potentials
[29]. In addition, TRPV1 receptor is activated and sensi-
tized by acidic pH; a condition that leads to pain during
inflammation and ischemia [30,31].
Peripheral and spinal TRPV1 receptor distribution
TRPV1 receptor has been found in both the peripheral
and central nervous system within centres known for
their role in pain detection, transmission and regulation,
consistent with its key role in pain. Indeed, TRPV1
receptor is expressed in all sensory ganglia (DRG, TG,
Vagal) and in small sensory C and Aδ fibers, which may
contain various neuropeptides including substance
P (SP) and/or calcitonin gene-related peptide (CGRP)
[12,32-41]. These fibers terminate predominantly in
lamina I and II of the superficial dorsal horn [42,43].
TRPV1 receptor is also expressed postsynaptically on
lamina II cell bodies [43] and within the lateral collateral
path, where the majority of visceral afferents terminate
[44]. Spinal cord TRPV1 receptor labelling has mainly
been found in the lumbar segment L4-L6 and preferen-
tially expressed by visceral afferents [44]. TRPV1 recep-
tor is also expressed in glial cells in lamina I and II
dorsal horn of the spinal cord [45]. Capsaicin stimulates
excitatory and inhibitory transmission at dorsal horn
level [46,47]. In particular, TRPV1 receptor stimulation
induces the release of substance P, which in turn excites
inhibitory neurons in laminae I, III and IV resulting in
the enhancement of GABA- and glycinergic inhibitory
post synaptic currents (IPSCs) [48-50].
TRPV1 receptor and inflammatory pain
Phosphorylation and dephosphorylation reactions regu-
late TRPV1 receptor activity and proved to be crucial in
promoting inflammatory pain. Activation of TRPV1
receptor during inflammation appears to be a dynamic
process that is produced by the combination of endo-
genous ligands, phosphorylation, low pH and body tem-
perature. Pro-inflammatory agents such as nerve growth
factor (NGF), ATP, bradykinins, serotonin, histamine,
proteases and chemokines lead to TRPV1 sensitization
through phospholipase C activation. PLC-induced sensi-
tization reduces the threshold for detecting painful sti-
muli during inflammatory pain [51-54].
TRPV1-/- mice have shown markedly decreased ther-
mal hyperalgesia in inflammatory pain models, confirm-
ing that the sensitization of these channels is likely
to be involved in this phenomenon [55,56]. TRPV1
receptor activity is also modulated by phosphatidylinosi-
tol-4,5-bisphosphate (PIP2) via the activation of phos-
pholipases like PLC. Two opposing effects have been
reported on TRPV1 receptor activity by PIP2. It can
both activate and inhibit TRPV1 receptor depending on
the experimental conditions, or more specifically on the
level of stimulation of the channel. PIP2 plays a role in
desensitization of TRPV1 receptor; a condition that
causes TRPV1 activation-induced currents decay during
prolonged activation. Calcium flowing through TRPV1
channel activates a Ca2+-sensitive PLC, which hydrolyzes
PIP2 and leads to its depletion, which in turn results in
diminished channel activity. TRPV1 channel currents
require PIP2 or other phosphoinositides since they may
be inhibited by scavenging endogenous phosphoinosi-
tides with polylysine and reactivated by the application
of PIP2 or other phosphoinositides [57,58]. Nonetheless,
it has also been discovered that after exposure of
TRPV1 receptor to high capsaicin concentrations, the
ensuing Ca2+ influx activates PLC, which results in the
depletion of PIP2 and PtdIns(4)P, which in turn reduces
channel activity leading to desensitization [57]. It has
been suggested that the balance between the inhibitory
and facilitatory effects of PIP2 on TRPV1 receptor
depends on the stimulation level of the channel, since
during sensitization PLC-coupled agonists induce a
moderate depletion of PIP2, removing its inhibitory
effect, although not producing low enough lipid levels to
inhibit channel activity. In contrast, high capsaicin con-
centrations induce a severe depletion of PIP2 that limits
channel activity and leads to desensitization [57]. On
this subject, TRPV1 receptor regulation by lipids seems
to be anything but simple. Moreover, it has recently
been suggested that ethanol enhances TRPV1 mediated
responses via PIP2-TRPV1 receptor interaction [58].
Phosphoinositide 3-kinase also modulates TRPV1 activity
by facilitating TRPV1 receptor trafficking to the plasma-
membrane in response to NGF released during inflam-
mation, leading to hyperalgesia (see forward section)
[59]. Other membrane-derived lipids also regulate
TRPV1 receptor activity. Prostaglandin E2 (PGE2) and
prostacyclin I2 (PGI2) enhance capsaicin-induced current
in DRG [60] and reduce the temperature threshold for
TRPV1 receptor activation [61]. PGE2 increases cAMP
levels and therefore activates PKA, which directly phos-
phorylates the channel [62] within Thr 144, Thr 370, and
Ser 502 residues which have been implicated in sensitiza-
tion of heat-evoked TRPV1 receptor responses, suggest-
ing a role for PKA in the development of thermal
hyperalgesia [63]. Oleylethanolamide (OEA), a natural
analogue of the endogenous cannabinoid anandamide,
anandamide itself and some lipoxygenase products such
as 12- and 15-HPETEs (hydroperoxyeicosatetraenoic
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acids) and 5- and 15-HETEs (hydroxyeicosatetraenoic
acids) all positively modulate TRPV1 receptor function
[17,64].
Chronic pain-induced sensitization also intensifies the
expression of TRPV1 receptor in sensory neurons
through transcriptional and translational regulation,
post-translational changes and altered trafficking, contri-
buting to the development of pathological pain states in
which increased sensitivity to noxious stimuli occurs
[65]. NGF retrograde transport increases the translation
of TRPV1 receptor in the cell body during inflammation
resulting in an increased translation of TRPV1 receptor
to the cell body [66]. NGF also activates phosphoinositide
3-kinase (PI3K)-SRC kinase signalling pathway which
phosphorylates intracellular stores of TRPV1 leading to
its assembly within the cellular membrane [67].
TRPV1 receptors and neuropathic pain
The nerve growth factor (NGF), which plays a major
role in the development and maintenance of neuro-
pathic pain following peripheral nerve injury [68] has
been proven to up-regulate TRPV1 receptor [69] and be
involved in the phenotypic changes which lead to the
development of neuropathic pain. TRPV1 receptor is
up-regulated in undamaged neurons and down-regu-
lated in damaged ones in several models of neuropathic
pain [70] and, interestingly, the increased expression of
TRPV1 receptor is related not only to the C-fibers but
also to the myelinated A-fibers, which justifies the effec-
tiveness of TRPV1 receptor agonist/antagonists in
mechanical allodynia, apart from thermal hyperalgesia.
In the tight ligation of the L5 spinal nerve, another
model of neuropathic pain, the expression of TRPV1
receptors in the injured L5 dorsal root neurons
decreased, whereas it increased in the uninjured L4 dor-
sal root neurons [70]. The up-regulation of the TRPV1
receptor at peripheral and central nervous system level
in neuropathic pain conditions provides morphological
evidence that the sensitivity of the vanilloid system in
this painful condition is increased (conversely to the
opioid system), therefore making the TRPV1 channel a
suitable candidate for the future development of novel
neuropathic pain relieving agents. TRPV1 receptor up-
regulation also appears to occur at central sites leading
to an enhancement of glutamatergic signalling in the
spinal cord [71]. Similarly to peripheral sites, sensitiza-
tion associated with an up-regulation of spinal TRPV1
receptor is thought to be at the base of the development
of mechanical allodynia in the chronic constriction
injury of the sciatic nerve [72].
The increased expression of TRPV1 receptor in patho-
logical pain conditions [73] and its desensitization prop-
erty associated with stimulation presents a valid strategy
for pain relief and opens up the perspective of curing
currently untreatable conditions such as neuropathic
pain. Topical application of capsaicin proved effective in
different neuropathic pain conditions, including post-
herpetic neuralgia [74] and surgical neuropathic pain
[75] but ineffective in chronic distal painful polyneuro-
pathy [76]. However, topical capsaicin treatment such as
creams, lotions or patches is associated with irritation,
discomfort and pain due to the activation of sensory
neurons expressing TRPV1 receptors in humans. This
factor has driven chemical synthesis towards novel vanil-
loids with an improved desensitization/pungency ratio.
The mechanisms at the basis of the anti-hyperalgesic
action of topically applied capsaicin in neuropathic pain
induced by partial sciatic nerve injury have been investi-
gated. The novel expression of TRPV1 receptors on
neonatal capsaicin-insensitive fibers confirmed
by immunohistochemistry accounted for the anti-
hyperalgesic action of topical capsaicin [77]. TRPV1-/-
mice show normal responses to noxious mechanical
stimuli but exhibited no vanilloid-evoked pain beha-
viour, reduced detection of painful heat and limited
thermal hypersensitivity in the setting of inflammation.
TRPV1 channels appear to be essential to the selective
detection of pain sensations and to thermal hyperalgesia
associated with inflammatory pain [55,56]. Vanilloid
application on sensory neurons causes pain symptoms
such as thermal hyperalgesia and mechanical allodynia
similar to those associated with neuropathic pain
[78,79]. Indeed TRPV1 receptor blockers should prove
to be analgesics in neuropathic pain conditions. Early
studies using capsazepine, the prototype TRPV1 antago-
nist, failed to produce any analgesic effect in models of
acute and chronic pain in rats [80]. Subsequently, stu-
dies using capsazepine have shown that this drug inhib-
ited noxious heat, protons and capsaicin-induced
responses on cloned human [81] or guinea pig [82]
TRPV1 receptors, whereas it failed to inhibit the
responses to low pH on rat TRPV1 receptors, thus indi-
cating possible species differences in the pharmacology
of TRPV1 receptors. Interestingly, capsazepine reversed
hind paw capsaicin-, CFA- and carrageenan-induced
thermal hyperalgesia and mechanical allodynia in mod-
els of inflammatory and neuropathic pain in the guinea
pig [83]. Capsazepine was also effective in reversing par-
tial sciatic nerve ligation-induced mechanical hyperalge-
sia in such rodents while it exhibited little analgesic
effect in mice or rats with neuropathic and inflamma-
tory pain. This species-specificity in capsazepine phar-
macological action has led to the development of new,
potent and selective TRPV1 antagonists. Pharmaceutical
companies have been expressing a great interest in the
development of potent and selective TRPV1 antagonists.
A potent, selective, and orally bioavailable antagonist of
rat TRPV1, the N-(4-tertiarybutylphenyl)-4-(3-
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chloropyridin-2-yl)tetrahydropyrazine-1(2H)-carbox-
amide, BCTC, has been developed by Valenzano et al.
[84] and tested in models of chronic pain in rats. BCTC
exhibited pain relief in mechanical and thermal hyperal-
gesia induced by intraplantar injection of capsaicin or
CFA. BCTC also reduced already established mechanical
hyperalgesia and tactile allodynia 2 weeks after partial
sciatic nerve injury, and did so with a safe side effect
profile [85]. Another potent and selective antagonist of
both human and rat TRPV1 receptors, the 1-isoquino-
lin-5-yl-3-(4-trifluoromethyl-benzyl)urea, A-425619,
proved dose dependently effective in several models of
inflammatory and postoperative pain. A-425619 showed
efficacy after either oral and intrathecal administration
or local injection into the inflamed paw. Furthermore,
A-425619 also showed partial efficacy in models of neuro-
pathic pain without altering motor performance [86].
Similarly, (E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b]
[1,4]dioxin-6-yl)acrylamide, AMG 9810, a competitive
antagonist of TRPV1 receptors, has been shown to
reverse thermal and mechanical hyperalgesia associated
with CFA-induced inflammatory pain without any sig-
nificant effect on motor function [87]. Two further
potent TRPV1 receptor antagonists, one with high and
the other with low CNS penetration (the 1-[3-(trifluor-
omethyl)pyridin-2-yl]-N-[4-(trifluoromethylsulfo-nyl)
phenyl]-1,2,3,6-tetrahydropyridine-4-carboxamide,
A-784168, and the N-1H-indazol-4-yl-N’-[(1R)-5-piper-
idin-1-yl-2,3-dihydro-1H-inden-1-yl]urea, A-795614,
respectively), delivered through different administration
routes (oral, intrathecal or intracerebroventricular),
clarified that peripheral, spinal and supraspinal TRPV1
receptors are all involved in analgesic actions in
inflammatory pain conditions. Moreover, centrally
penetrating TRPV1 receptor antagonists proved more
effective compared to peripheral restricted agents with
the same pharmacokinetic and pharmacological profile
[88], underlining an involvement of central TRPV1
receptor blockade in the analgesic action. A piperazi-
nylpyrimidine analogous, AMG517, was shown to
reverse inflammation-induced pain behaviour in rats, target
central TRPV1 receptor and have a long half-life that may
be amenable to a one-a-week administration [88,89]. How-
ever, during a double blind, placebo controlled, randomized,
parallel group, multicenter study for the management of
pain following molar extraction, TRPV1 receptor antago-
nists caused prolonged hyperthermia (> 40°C) after taking a
2 mg dose, thus revealing the importance of TRPV1 recep-
tor in central core temperature regulation [90]
TRPV1 receptor antagonists and body
temperature
Most TRPV1 receptor antagonists described to date
cause modest dose-limited increases in body
temperature in preclinical studies [91]. Studies using
TRPV1 knockout mice have unequivocally demonstrated
that TRPV1 receptor antagonist-elicited hyperthermia is
TRPV1 mediated [92]. Moreover, the magnitude and
duration of temperature elevation caused by TRPV1
antagonists proved to be dependent on the specific
properties (pharmacokinetic profile, specific modality of
TRPV1 blockade) of the individual TRPV1 receptor
antagonists [93,94]. Indeed, the temperature elevation
caused by the clinical candidate TRPV1 receptor antago-
nist ABT-102 was modest (0.6°C) and transient [94]
compared to that observed with AMG-517 (1.6°C) [93].
However, the fact that numerous structurally distinct com-
pounds blocking TRPV1 receptor cause hyperthermia indi-
cates that TRPV1 receptor is tonically active in controlling
body temperature in non-pathological states [91,93]. Several
efforts have been made in order to eliminate hyperthermia-
related side effects from TRPV1 receptor blockade. Such
efforts have led to the development of profile C modulators
such as the (R,E)-N-(2-hydroxy-2,3-dihydro-1H-inden-4-
yl)-3-(2-(piperidin-1-yl)-4 (trifluoromethyl)phenyl)acryla-
mide, AMG8562. AMG8562 blocks capsaicin activation of
TRPV1 receptor, does not affect heat activation of TRPV1
receptor, potentiates pH 5 activation of TRPV1 receptor in
vitro, and does not cause hyperthermia in vivo in rats.
AMG8562 has been found to significantly block capsaicin-
induced flinching behaviour, produces statistically
significant efficacy in complete Freund’s adjuvant- and skin
incision-induced thermal hyperalgesia, and acetic acid-
induced writhing model, with no profound effects on motor
activity [95]. The hurdle of TRPV1 antagonist-hyperthermia
therefore seems to be at a turning point.
Towards hybrid compounds targeting TRPV1 and
cannabinoid receptors
Several studies are emerging which highlight the fact
that the analgesic effects of compounds that interact
with the endocannabinoid system are also mediated by
TRPV1 channels. This is due to the fact that some
endovanilloids/endocannabinoids such as anandamide
may activate TRPV1 and cannabinoid receptors. It is
not surprising then that the effectiveness of AM404, an
inhibitor of endocannabinoid cellular uptake, in alleviat-
ing neuropathic pain has been attributed (at least in
part) to TRPV1 receptor stimulation [96]. Cannabidiol is
a major component of Cannabis Sativa and its analgesic
effect was prevented by capsazepine in a model of neu-
ropathic pain [97]. The inhibition of the metabolism of
endocannabinoids by blocking the enzyme fatty acid
amide hydrolase, FAAH, proved to be effective in neuro-
pathic pain [98]. FAAH inhibition, by elevating the
levels of anandamide and other N-acylethanolamine
besides cannabinoid involves TRPV1 receptors. It is
worth noting that in a study carried out by Maione et
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al. [99], N-arachidonoyl-serotonin (AA-5-HT), a dual
FAAH inhibitor and TRPV1 receptor blocker, proved to
be analgesic after repeated administration in rats in the
sciatic nerve ligation model of neuropathic pain. When
compared to much more potent FAAH inhibitors
(URB597 and OL135), AA-5-HT showed similar or even
greater effectiveness, hence confirming the role of
TRPV1 receptor blockade in alleviating symptoms of
neuropathic pain. Therefore by simultaneously targeting
FAAH enzyme and TRPV1 receptors, two different tar-
gets controlling nociception in distinct ways, this hybrid
molecule could represent an alternative approach to be
used in the treatment of neuropathic pain. Such a strat-
egy might even solve the problems of the hyperthermia
caused by some “pure” TRPV1 antagonists, since AA-5-
HT does not cause such side effect (possibly because
indirect activation of CB1 receptors might be the cause
of hypothermia).
Nociceptive fiber deletion by TRPV1 activation
As an alternative to TRPV1 receptor antagonism, thera-
peutic nociceptive cell deletion, exploiting the enriched
TRPV1 receptor expression in nerve terminals of dorsal
root or trigeminal ganglia, has been proposed as a stra-
tegic approach to the management of severe pain. In
fact persistent activation of TRPV1 receptors induces a
strong and prolonged increase in intracellular Ca2+,
leading to excitotoxicity which compromises and deletes
TRPV1-expressing cells [100]. Over-stimulation of
TRPV1 receptor would prove useful in deleting TRPV1
receptor-positive neurons, thereby eliminating any sensi-
tivity to nociceptive stimuli in hyperalgesic conditions
such as inflammatory or neuropathic pain, without
affecting normal sensory transmission involving fibers
that do not express TRPV1 receptors. RTX application
to dorsal root or trigeminal ganglia selectively ablates
vanilloid-sensitive nociceptive neurons, while leaving
other adjacent neurons unaffected. Such treatment
blocked experimental inflammatory hyperalgesia and
neurogenic inflammation in rats and naturally occurring
cancer and debilitating arthritic pain in dogs. Interest-
ingly, sensations of touch, proprioreception and high
threshold mechanonociception were unaffected [101].
Similarly, in rats perineural RTX application to the
sciatic nerve inhibited inflammatory hyperalgesia in a
dose- and time-dependent manner, despite leaving pro-
prioreceptive and nociceptive sensations and motor con-
trol unaffected [102]. In rats already exhibiting
neuropathic pain, RTX injection into the dorsal root
ganglia of the L3, L4, L5 and L6 nerve roots increased
the withdrawal threshold showing that the TRPV1-posi-
tive neurons mediate the most sensitive part of mechan-
ical allodynia. When RTX was administrated into the
ipsilateral dorsal root ganglia before nerve injury, such
treatment prevented the development of tactile allodynia
in 12 out of 14 rats. Immunohistochemical staining
revealed that the TRPV1 receptor positive neurons were
eliminated in rats that did not develop tactile allodynia,
whereas they were still present in the allodynic rats.
RTX injection in sensory ganglia could therefore repre-
sent an effective and broadly applicable strategy for pain
management in neuropathies [103].
Towards supraspinal TRPV1 receptor and the
activation of an antinociceptive descending
system
TRPV1 receptors have been identified in various regions
of the brain known for their role in pain transmission
or modulation [104-106] such as RVM, PAG, amygdala,
solitary tract nucleus, somatosensory cortex, anterior
cingulated cortex and insula [107,108]. TRPV1 receptor
has been found on astrocytes, perivascular structures
and neuron cell bodies and dendrites mainly on postsy-
naptic spines [104,105,109-111]. Capsaicin evokes gluta-
mate release from slices of hypothalamus in a Ca2
+-dependent way [110]. Such an effect was proven to be
inhibited by capsazepine, suggesting that TRPV1 recep-
tor may be expressed on glutamatergic neurons in the
hypothalamus [110].
An earlier role of supraspinal TRPV1 receptor on pain
transmission and modulation was evidenced by intracer-
ebroventricular (ICV) capsaicin injections which
decreased nociceptive threshold and reduced morphine-
and stress-induced analgesia [111,112]. Conversely, ICV
capsazepine or ruthenium red, another TRPV1 receptor
antagonist, attenuated nocifensive behaviour induced by
an intradermal injection of capsaicin or formalin in
mice [113]. An effect of capsaicin involving supraspinal
structures was also observed after systemic capsaicin
administration. This treatment increased the firing activ-
ity of locus coeruleus (LC) neurons, an area which is
activated by painful stimuli and whose stimulation pro-
duces antinociception even after sensory nerve fiber
destruction [114,115]. Accordingly, TRPV1 receptor
activation with capsaicin increased glutamatergic minia-
ture excitatory postsynaptic currents in LC [116] and
when injected into the ventral segmental area enhanced
dopaminergic output to the nucleus accumbens [117].
Activation of the TRPV1 receptor also evokes gluta-
mate release in the cortex [118]and capsaicin application
to the somatosensory cortex reduced mechanically and
electrically evoked potentials of anesthetized rats [119]
and increased the firing rate of some neurons while
depressing firing of other neurons in anterior cingulate
cortex, an area involved in pain-related memory and
descending modulation of nociception [120-122].
In one of our earlier studies, the intra-dorsolateral
(DL) PAG microinjection of capsaicin increased the
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latency of the nociceptive reaction in the plantar test.
This analgesic effect required glutamate release and sub-
sequent activation of glutamate receptors such as group
I metabotropic glutamate (mGlu) and N-methyl-D-
aspartate (NMDA) receptors. Indeed riluzole, a voltage-
dependent Na+ channel blocker that enhances the
uptake of glutamate, mGlu subtypes I and 5 (mGlu1
and mGlu5) and NMDA receptor antagonists blocked
the analgesic effect induced by capsaicin [123]. We pro-
posed that capsaicin-induced antinociception was due to
the activation of the descending antinociceptive pathway
via a TRPV1 receptor-dependent increase in glutamate
release and the downstream activation of postsynaptic
mGlu1/5 and NMDA receptor. The microinjection of
capsaicin within the DL PAG induced brief hyperalgesia
followed by analgesia in another study where a higher
concentration of capsaicin was used [124]. TRPV1
receptor activation and the consequent desensitization
may have been responsible for the observed effects, due
to the fact that sustained activation of TRPV1 receptor
leads to its desensitization. In another of our studies
intra-VL PAG administration of URB597, an inhibitor of
FAAH, by raising the endocannabinoid level resulted in
a dose-dependent dual effect on pain responses depend-
ing on TRPV1 or CB1 receptor stimulation [125].
Indeed, the different recruitment of CB1 or TRPV1
receptors by the increased endocannabinoid/vanilloid
level may lead to hyperalgesia or analgesia. Hyperalgesia
was proposed to be due to CB1 receptor stimulation
which leads to inhibition of the antinociceptive PAG-
RVM descending pathway. Higher doses of URB597
caused rapid analgesia blocked by capsazepine, being
due to TRPV1 receptor stimulation. Therefore, by acting
on either CB1 or TRPV1 receptor within the PAG,
endocannabinoids lead to pronociceptive and antinoci-
ceptive effects through an inhibitory or facilitatory
action on the pain descending pathway. Consistently,
the same study showed that some neurons within the
PAG coexpressed TRPV1 and CB1 receptors.
The intra- VL PAG microinjection of the FAAH and
TRPV1 receptor blocker, AA-5-HT, induced analgesia in
several pain models, such as tail flick, plantar and for-
malin tests. AA-5-HT also depressed the RVM OFF cell
as well as ON cell activity. RVM ON and OFF cells
represent an electrophysiological method for investigat-
ing the analgesic potential of drugs acting centrally.
Indeed, morphine causes an increase in the activity of
OFF cells (which are defined as antinociceptive) and an
inhibition of the ON cells (pronociceptive). Being
analgesic, AA-5-HT should have induced an increase in
the OFF cell activity. The effect of AA-5-HT was
mimicked by co-injecting the selective FAAH inhibitor
URB597 (which blocks FAAH activity) in combination
with I-RTX (which blocks TRPV1 receptors).
Accordingly, analgesia was induced together with inhibi-
tion of ongoing ON and OFF cell activities. The recruit-
ment of an ‘’alternative’’ pathway, identified as PAG-
locus coeruleus (LC)-spinal cord was attributed to the
AA-5-HT-induced effect. Indeed, intra-VL PAG AA-5-
HT increased LC neuron firing activities while intrathe-
cal phentolamine or ketanserin prevented the analgesic
effect of AA-5-HT. Moreover, intra-PAG AA-5-HT pre-
vented the changes in the ON and OFF cell firing activ-
ity induced by intra-paw formalin, and it reverted the
formalin-induced increase in LC adrenergic cell activity.
All AA-5-HT effects were antagonized by cannabinoid
CB1 and TRPV1 receptor antagonists, thus suggesting
that co-localization of these receptors in the PAG could
be an appropriate neural substrate for AA-5-HT-
induced antinociception [126].
The direct stimulation of TRPV1 receptors by micro-
injection of capsaicin into the VL PAG increased the
latency of the nociceptive reaction [127] as it did in the
DL-PAG [123]. The antinociceptive effect of capsaicin
when microinjected into the VL PAG was accompanied
by an increase in glutamate release in the RVM. Block-
ade of TRPV1 receptors by I-RTX prevented capsaicin-
induced antinociception and the increase in RVM
glutamate release. At a higher dose, I-RTX facilitated
nociceptive response and lowered the release of gluta-
mate, suggesting that within the VL PAG, TRPV1
receptors tonically stimulate glutamatergic output to the
RVM, and concomitantly inhibit nociception [127]. The
VL PAG shows a high density of TRPV1 receptor posi-
tive profiles with strong immunoreactivity mostly found
in cell bodies. The high density of vesicular glutamate
transporter 1 (VGLUT1) on nerve terminals surround-
ing TRPV1 receptor positive cells may indicate glutama-
tergic input on TRPV1-expressing cells. In the VL PAG,
many fibers were also vesicular GABA transporter
(VGAT) positive, and VGAT-immunoreactivity was
observed around TRPV1 receptor positive cells, demon-
strating that TRPV1-expressing neurons could also
receive GABAergic inputs [127]. In accordance with
behavioral studies, McGaraughty et al. [124] found that
microinjection of capsaicin into the DL PAG produced
an initial activation, followed by a decrease, in the tail
flick related ON-cell burst of activity and an increase in
OFF-cell spontaneous firing.
Microinjection of capsaicin into the VL PAG caused a
decrease in the firing activity of the ON cells and a very
rapid increase in the firing activity of the OFF cells.
Conversely, intra-VL PAG I-RTX increased the firing
activity of ON cells while decreasing the firing activity
of the OFF cells. Intra-VL PAG capsaicin also decreased
tail flick-induced ON cell peak firing and delayed the
onset of OFF cell pause. Thus, stimulation of TRPV1
receptor within the DL and VL subregion of the PAG
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seems to lead to activation of the antinociceptive OFF
cells and inhibition of the pronociceptive ON cells, con-
sistent with the behavioural analgesia. These effects
were prevented by pre-treatment with I-RTX at a dose
which did not significantly change the ongoing RVM
ON and OFF cell activities per se. At a higher dose,
I-RTX increased the duration of the OFF cell pause and
shortened its onset [127].
As a whole, this evidence shows that pharmacological
manipulation of TPRV1 receptor within the PAG may
be a suitable strategy to activate the antinociceptive
PAG-RVM-dorsal horn circuitry for producing analgesia
[see 128 for review].
Does TRPV1 receptor have a role in microglia/
astrocytes-mediated synaptic plasticity?
Until recently, pain had been thought to arise primarily
from the dysfunction of neurons. Recent evidence, how-
ever, suggests that neuro-immune changes might also
contribute to pain following injury to the nervous sys-
tem. Glial cells involved in mediating inflammatory pro-
cesses are resident within the spinal cord and include
both astroglia and microglia, the latter of which has
been directly implicated in the initiation of peripheral
injury-induced pain [129]. Moreover, microglia have
been shown to express cannabinoid receptors [130] and
to produce and inactivate endocannabinoids [131,132].
In addition, it has been proposed that TRPV1 receptor
activation mediates microglial cell death in vivo and in
vitro via Ca2+-mediated mitochondrial damage and cyto-
chrome C release [133] and that TRPV1 receptor in
astrocytoma cells can contribute to apoptosis via Ca2+
influx and the activation of p38 [134]. Thus, besides the
crucial role of TRPV1 channels in sensory neurons,
where they regulate acute thermal nociception and
inflammatory hyperalgesia, the investigation of the role
of these receptors on glia and microglia could provide a
new tool in further investigation into chronic diseases
such as neuropathic pain. In fact, a contribution of
TRPV1 receptors in glia and microglia activation has
been demonstrated at the spinal level in mice with
acute, inflammatory and neuropathic pain. In particular,
it has been suggested that TRPV1 receptor-knockout
mice show a higher density of astrocytes and microglia
positive profiles under normal conditions than their
wild-type littermates. Inflammatory or neuropathic pain
induced a increase in glia and microglia in wild- type
than in knockout mice, although the latter showed
increased glial immunoreactivity as compared to
untreated/uninjured animals. Thus, TRPV1 receptor
could be involved in activating spinal glia in mice in dif-
ferent pain models including neuropathic pain and may
have varying underlying mechanisms at different stages
during the progression of the pain state [135]. However,
the role of TRPV1 channels in glial and microglial phe-
notypical changes and at supraspinal level needs and
deserves further investigation.
Conclusion
The few findings about the role of supraspinal TRPV1
receptors in controlling pain appear encouraging. The
possible exploitation of TRPV1 receptor for activating
the antinociceptive descending pathway at PAG level
may be a strategy of interest. Indeed a direct agonist
such as capsaicin, an indirect one such as URB597 or an
hybrid anadamide hydrolysis and TRPV1 receptor
blocker such as AA-5-HT, lead to analgesia. TRPV1
receptor stimulation is associated with increased gluta-
mate release and activation of group I mGlu and
NMDA receptors and with modulation of downstream
RVM ON and OFF neurons. Immunohistochemical data
strongly support the hypothesis that the activation/inhi-
bition of TRPV1 receptor expressed on glutamatergic
neurons following intra-PAG injection of capsaicin/I-
RTX leads to an increase/decrease in glutamate release
and behavioural analgesia/hyperalgesia. Exogenous com-
pounds capable of activating TRPV1 channels or strat-
egy increasing endovanilloids within the PAG-RVM
counteract nociception. Thus, TRPV1 receptor (and
hopefully other TRP channels such as TRPA1 and
TRPM8 which often co-localize with TRPV1 on periph-
eral nerve terminals) may offer a suitable target for
enhancing the activity of the endogenous antinociceptive
descending pathway and producing analgesia. Moreover,
hybrid molecules with a dual mechanism, such as AA-5-
HT, which blocks FAAH activity and TRPV1 receptors,
do not induce hyperthermia as “classic” TRPV1 antago-
nists do. As well as the PAG-RVM antinociceptive axis,
other regions of the brain known to influence descend-
ing pain modulation, such as the amygdala, thalamus
and LC show TRPV1 receptor localization, although the
exact contribution of such receptors, if any, has yet to
be determined. Further studies to clarify the role of the
supraspinal TRPV1 receptor and in particular, within
the antinociceptive descending pathway, may open the
way to a novel strategy of pain relief in central nervous
system disorders, such as neuropathic pain, which does
not yet have an appropriate therapy.
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